IMPACT OF TIMING OF 4F-PCC ADMINISTRATION ON OUTCOMES IN ORAL FACTOR XA INHIBITOR-ASSOCIATED ICH

被引：0
|
作者：
Jaszcz, Sarah [1 ]
Wein, Rachel [1 ]
Mangan, Kyle
Mohamed, Wazim [2 ]
Parker, Dennis [3 ]
机构：
[1] DETROIT MED CTR, DETROIT, MI USA
[2] Wayne Hlth, Greenville, OH USA
[3] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
来源：
CRITICAL CARE MEDICINE | 2025年 / 53卷 / 01期
关键词：
D O I：
10.1097/01.ccm.0001104104.33520.99
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding
    Brown, Caitlin S.
    Mattson, Alicia E.
    Cabrera, Daniel
    Coelho-Prabhu, Nayantara
    Rabinstein, Alejandro A.
    Dettling, Theresa
    McBane II, Robert D.
    Bellolio, Fernanda
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 73 : 1 - 6
  • [32] Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series
    Reynolds, Tessa R.
    Gilbert, Brian W.
    Hall, Katherine M.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (05) : 755 - 760
  • [33] OUTCOMES FROM THE PITCH STUDY: 4-FACTOR PCC IN INTRACRANIAL XA INHIBITOR COAGULOPATHY HEMORRHAGES
    Goad, Nathan
    Sanchez, Patricia
    Levesque, Melissa
    Wilson, Jason
    Pesquera, Jorge
    Kasischke, Karl
    Schutt, Charles
    Renati, Swetha
    Burgin, William
    Rose, David
    CRITICAL CARE MEDICINE, 2020, 48
  • [34] Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients
    Highsmith, Emily A.
    Morton, Celia
    Varnado, Sara
    Donahue, Kevin R.
    Sulhan, Suraj
    Lista, Annette
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (05): : 598 - 605
  • [35] Evaluation of the impact of weight estimations on anticoagulation reversal with 4-factor prothrombin complex concentrate (4F-PCC) in the emergency department
    Vidal, Jennifer
    Procopio, Gabrielle
    Faley, Brian
    PHARMACOTHERAPY, 2016, 36 (12): : E230 - E230
  • [36] Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use
    Uttaro, Elizabeth
    Young, Mikaela R.
    Falvey, Jennifer
    Corvelli, Jenna M.
    Acquisto, Nicole M.
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (05)
  • [37] Outcomes Associated With Andexanet Use in Patients With Factor Xa Inhibitor-Associated Intracranial Hemorrhage: A One-Year Single-Center Analysis
    Concha, M.
    Shomo, E.
    Busey, K., V
    Case, D.
    Brockhurst, A.
    Giovino, A.
    ANNALS OF EMERGENCY MEDICINE, 2019, 74 (04) : S80 - S80
  • [38] Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review
    Costa, Olivia S.
    Baker, William L.
    Roman-Morillo, Yuani
    McNeil-Posey, Kelly
    Lovelace, Belinda
    White, C. Michael
    Coleman, Craig, I
    BMJ OPEN, 2020, 10 (11):
  • [39] Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing
    Chiasakul, Thita
    Crowther, Mark
    Cuker, Adam
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (02)
  • [40] Recent Exposure to Four-Factor Prothrombin Complex Concentrate (4F-PCC) is Associated with Intracardiac Thrombus during Liver Transplantation.
    Misel, M.
    Schnickel, G.
    Berumen, J.
    Sanchez, R.
    Mekeel, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 558 - 558
12345